Novo Integrated Sciences Inc Stock Price, News & Analysis

On March 23, 2023, Novo Integrated Sciences (NASDAQ: NVOS) announced updates regarding their Share Purchase Agreement with SwagCheck Inc., which is yet to close as of January 10, 2023. The company faced compliance issues with Nasdaq due to delayed filings, but was granted an extension until May 29, 2023, to file the necessary reports. Between February and March 2023, Novo issued over 7 million shares from various agreements, increasing their total outstanding shares to 144,257,518. Currently, the company has a minimal outstanding balance of $50,000 on one note, while two other notes have been fully paid off.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced that it received a notice from Nasdaq on January 25, 2023, for failing to comply with continued listing requirements due to late filings of its Annual Report (Form 10-K) for the fiscal year ended August 31, 2022, and its Quarterly Report (Form 10-Q) for the quarter ended November 30, 2022. Following a prior notice on December 15, 2022, Novo has until February 13, 2023, to submit a plan to regain compliance. If accepted, it could extend the compliance deadline to June 12, 2023. Novo is committed to filing the necessary reports promptly to rectify this situation.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) has provided an update regarding the SWAG Agreement for purchasing 100% of SwagCheck Inc. shares, initially set to close by January 10, 2023. Although not closed, both parties are working towards completion. Additionally, the company has issued over 19 million shares to warrant and note holders. As of January 16, 2023, the total outstanding shares stood at 59,637,859. Novo is currently finalizing its audit for the fiscal year ending August 31, 2022 and plans to file its Annual Report on Form 10-K shortly.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced receipt of a compliance notice from Nasdaq regarding delays in filing its Annual Report on Form 10-K for the fiscal year ended August 31, 2022. The Company has until February 13, 2023, to submit a compliance plan to Nasdaq, and if accepted, may receive an extension until June 12, 2023, to file the report. The Company aims to file the Form 10-K promptly to regain compliance with Nasdaq regulations.

Novo Integrated Sciences (NASDAQ: NVOS) has entered a Consulting Agreement with Sarfez Pharmaceuticals, focusing on the marketing and distribution of SOAANZ®, an FDA-approved loop diuretic for patients with heart failure and edema. This partnership aims to enhance patient quality of life and minimize bladder issues associated with traditional diuretics. SOAANZ® offers extended effects and is suitable for patients with underlying bladder sensitivities. Novo’s subsidiary, Clinical Consultants International, will leverage its network to promote SOAANZ® to healthcare providers.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) has signed a Sales and Consulting Agreement with TiaTech USA Inc., which includes revenue-sharing potential. This partnership aims to enhance healthcare interconnectivity through TiaTech's ecosystem, which improves patient encounters and operational efficiency for healthcare providers. Dr. Joseph M. Chalil stated that TiaTech's solutions will benefit Novo's client network in the USA and Canada. The expected integration aims to address staffing shortages and streamline patient care through advanced technology, including telemedicine capabilities.

Novo Integrated Sciences (NASDAQ: NVOS) has announced a partnership with Tranquility Lifestyle Solutions (TLS) through a Sales and Consulting Agreement that includes revenue-sharing potential. This agreement aims to enhance home care for seniors using TLS's advanced technology platform, which integrates 4D radar sensors for fall detection and vital sign monitoring. The partnership has initiated two pilot projects with U.S. senior housing networks and a tertiary care hospital. This collaboration aligns with Novo's holistic approach to patient-first health and wellness.

Novo Integrated Sciences, Inc. (NASDAQ: NVOS) announced the pricing of a public offering of 4,000,000 units at $0.50 per unit, expected to close around October 18, 2022. Each unit comprises one share of common stock or pre-funded warrant, alongside two warrants, each exercisable at $0.50 per share. The offering could generate around $2 million in gross proceeds, aimed at debt repayment and general corporate purposes including potential acquisitions. Maxim Group LLC acts as the exclusive placement agent for this offering.

Novo Integrated Sciences (NASDAQ: NVOS) has entered a Consulting Services Agreement with Softhread, Inc., aimed at enhancing healthcare delivery through advanced IT solutions in the emerging Health Care 4.0 ecosystem. The agreement, which includes revenue-sharing potential, leverages Softhread's blockchain and AI-enabled platform to improve operational efficiency and security while addressing cybersecurity challenges in healthcare. Novo's CEO praised the collaboration, highlighting its significance in managing sensitive health information. This partnership aims to integrate innovative technologies into Novo's offerings, enhancing patient care and outcomes.